MOSCOW, March 29. /TASS/. American pharmaceutical company Eli Lilly has entered into an agreement with Swiss Swixx Biopharma, which among other things, stipulates the transfer of rights to supply medications to and sell them in Russia, as well as ensures compliance with current obligations regarding local production, a source in the press service of the company’s Russian representative office told TASS.
"Eli Lilly has entered into an agreement with Swixx Biopharma, which stipulates the transfer of rights to import the company’s products, sell them on Russian territory, as well as ensure compliance with current obligations regarding local production. The agreement will allow life-saving medications to continue to flow to Russia for patients that require treatment for diabetes, cancer, autoimmune and neurological diseases," the company said.
Eli Lilly continues supplying life-saving medications to Russia and taking necessary measures to ensure their uninterrupted access to Russian patients, the source added.
Earlier, Kommersant daily wrote citing former employees at the company’s Russian office that Eli Lilly intended to leave the Russian market and transfer its local business to a partner in Central and Eastern Europe, the distributor Swixx Biopharma.